Medinol gains more ground
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis contends preliminary injunction issued against its Dutch stent sales by the District Court of Appeals in The Hague will not affect pan-European stent availability. In a July 3 decision by the intermediary court, the BxVelocity bare-metal stent and Cypher drug-eluting stent are prohibited from sales or distribution in The Netherlands. The ruling overturns a 2001 preliminary decision by a lower court not to issue an injunction against the devices' sales, according to Medinol. Cordis' legal counsel said in a statement that while the company is "surprised by the ruling...the decision affects only local product sales, [which] are relatively small." The decision comes one week after a German court ruled in favor of Medinol in another patent dispute, enjoining against sales of Boston Scientific's Express, Express2 and Taxus stents in Germany. According to Medinol, the Munich patent office will hold a hearing July 9 to decide the validity of the two Cordis patents in question. Cordis maintains the Dutch ruling has no bearing on the September launch of its second-generation Select sirolimus-eluting stent in The Netherlands or across Europe...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.